89Bio Inc reports results for the quarter ended September 30 - Earnings Summary

89bio

08/11/2024 20:59

* 89Bio Inc  ETNB.OQ  reported a quarterly adjusted loss of
$1.39​​ per share for the quarter ended September 30, lower than
the same quarter last year, when the company reported EPS of -45
cents.  The mean expectation of eight analysts for the quarter
was for a loss of 64 cents per share. Wall Street expected
results to range from $-1.18 to -49 cents per share.
    * Reported revenue was zero​; analysts expected $535.71
thousand. 
    * 89Bio Inc's reported EPS for the quarter was a loss of
$1.39​.
    * The company reported a quarterly loss of $149.07 million.
    * 89Bio Inc shares had risen by 34.6% this quarter and
lost 10.8%
so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for 89Bio Inc is
29.50 
This summary was machine generated from LSEG data November 8 at
08:59 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.64          -1.39          Missed
 Jun. 30 2024      -0.57          -0.48          Beat
 Mar. 31 2024      -0.46          -0.54          Missed
 Dec. 31 2023                     -0.50